Part two of a three-part series aimed at helping drug and device manufacturers better navigate and understand the Veterans ...

Criminal enforcement of the Foreign Corrupt Practices Act was paused on February 10 by a Trump administration executive order ...

In the dynamic pharmaceutical industry, successful product launches are critical to business success. For small and midsized biotech firms, where the reliance on a few key assets is high, the stakes ...

Dr. Scherer’s commitment to oncology patients took him from medical practice to research to helming 3T Biosciences, which is developing a novel T cell targeting platform.

Jeff Coller and Michelle Kim explain the origin of the Center and how getting low-cost RNA based molecules into the hands of academics drives innovation.

Tarsus Pharmaceuticals is making a splash with Xdemvy, an eye drop that kills the demodex mites that cause inflammation and ...

Established in 1997, Ergomed is a global leader in delivering specialized services in oncology, rare disease, and complex trials to the pharmaceutical and biotech sectors. Our comprehensive support ...

In the life sciences sector, maintaining a strategic approach to tax planning has become increasingly complex, especially with ongoing regulatory changes affecting mergers, acquisitions, and how we ...

One of the biggest incentives for developing new therapies for rare pediatric cancers is the FDA’s rare pediatric disease Priority Review Voucher (PRV) program. If a drug in development meets the ...

In 2021, I explored the impact of COVID-19 on the biotech sector in the article “Private Equity and SPACs in the Biopharma and Biotech Landscape.” The results were surprising: In 2024, global ...